Fredun Pharmaceuticals Reports Strong Sales Growth Amid Rising Interest Expenses in June 2025 Results

Fredun Pharmaceuticals has recently reported its financial results for the quarter ending June 2025, showcasing notable developments in its performance metrics. The company has experienced a significant adjustment in its evaluation, with its score rising to 13 from 7 over the past three months, reflecting a positive shift in its financial standing.
In terms of net sales, Fredun Pharmaceuticals reported Rs 119.85 crore, marking a year-on-year growth of 52.06%. This robust sales performance indicates a favorable near-term trend. Additionally, the company’s profit before tax less other income (PBT) reached Rs 9.04 crore, which represents a year-on-year increase of 63.77%. This figure is the highest recorded in the last five quarters, further emphasizing the positive trajectory of the company's profitability.

Moreover, the profit after tax (PAT) also demonstrated strong growth, amounting to Rs 6.77 crore, reflecting a year-on-year rise of 63.9%. However, it is important to note that the interest expense for the latest six months has increased to Rs 14.68 crore, growing by 42.39% compared to the previous half-year period, indicating a rise in borrowing costs.

Overall, Fredun Pharmaceuticals is navigating a landscape of positive financial metrics alongside some challenges related to interest expenses.

Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.